Cure For The Common Cold Coming?
Looks like they’re on the right path:
Australian drug maker Biota Wednesday reported the stunning success of its antiviral compound, named Vapendavir.
Tested in 300 asthmatic patients infected with the cold-causing human rhinovirus, the clinical trial showed that cold symptoms eased quickly and the duration of the infection was shortened considerably.
Patients given a placebo experienced the worst cold symptoms at 2.5 days, whereas those dosed with Vapendavir began rapid recovery after just 1.7 days.
That sounds like a good thing, but it’s still a long way from appearing on your local store shelves.
I guess for the moment I’ll stick with over-the-counter remedies.